GLP-1 Receptor Agonists Linked to Lower Diabetic Eye Edema Risk
- Patients with type 2 diabetes taking glucagon-like peptide-1 receptor agonists experience a lower rate of diabetic macular edema development over extended periods compared with metformin, according to a...
- The study evaluating diabetic macular edema included 3,920 patients in each treatment cohort.
- A second presentation evaluated at the conference examined the need for traditional glaucoma surgery among 16,753 GLP-1 receptor agonist users and 16,753 matched non-users diagnosed with type 2...
Patients with type 2 diabetes taking glucagon-like peptide-1 receptor agonists experience a lower rate of diabetic macular edema development over extended periods compared with metformin, according to a research presentation highlighted by AJMC.
Diabetic Macular Edema Progression Rates Over Seven Years
The study evaluating diabetic macular edema included 3,920 patients in each treatment cohort. AJMC reported that DME development was similar between GLP-1 receptor agonists and metformin through the first year at 12.2% versus 12.7%. Divergence appeared at longer intervals, with GLP-1 receptor agonist users showing lower development rates at three years at 24.3% versus 27.9%, at five years at 29.8% versus 35.9%, and at seven years at 30.9% versus 39.5%.
Glaucoma Surgery Incidence Across Three Patient Cohorts
A second presentation evaluated at the conference examined the need for traditional glaucoma surgery among 16,753 GLP-1 receptor agonist users and 16,753 matched non-users diagnosed with type 2 diabetes and glaucoma. AJMC reported that the three-year cumulative incidence for trabeculectomy was 0.28% for the medication group compared with 0.63% for non-users. Tube shunt implantation rates reached 0.97% versus 2.12%, while cyclophotocoagulation stood at 0.39% versus 1.00%.
Macular Degeneration Odds and Contrasting Research Findings
Medical Daily reported a separate analysis of more than 300 million U.S. patient records presented at the same meeting, showing that GLP-1 users with type 2 diabetes had about 31% lower odds of macular degeneration after researchers accounted for diabetes, hypertension, or high cholesterol. Medical Daily noted that unadjusted data initially suggested a 68% higher risk, which flipped once underlying health factors were included.
This observation contrasts with a 2025 study published in JAMA Ophthalmology covering 138,334 adults aged 66 and older with diabetes in Ontario, Canada. Medical Daily reported that the 2025 study found GLP-1 users were more than twice as likely to develop wet macular degeneration at 0.2% versus 0.1% over three years. Mahyar Etminan, a co-author of the Canadian study cited by Medical Daily, stated that the findings do not support stopping the medications.
Legal Actions Involving Vision Loss Claims and Product Liability
Drugwatch reported that a separate legal front involves approximately 250 non-arteritic anterior ischemic optic neuropathy cases in federal court in Pennsylvania and hundreds more in New Jersey state court against Novo Nordisk. Ellen Relkin, a mass tort attorney interviewed by Drugwatch, stated that these product liability lawsuits focus on a failure-to-warn theory regarding permanent vision loss from NAION. Drugwatch noted that NAION occurs when blood flow to the optic nerve suddenly stops, with no known treatment.
Ophthalmic Screening and Clinical Management Recommendations
Dr. Brenda Mulenga, a consultant ophthalmic surgeon cited by the Cayman Compass, stated at a healthcare conference that the benefits of GLP-1 medications heavily outweigh eyesight risks for most patients with type 2 diabetes. The Cayman Compass reported that Dr. Mulenga recommends manageable precautions, including regular eye checks by an ophthalmologist, particularly at the start of treatment. Medical Daily noted that patients with type 2 diabetes already require yearly dilated eye exams to check for diabetic retinopathy, providing an opportunity to monitor the macula.
